Pawel Komarnicki
Overview
Explore the profile of Pawel Komarnicki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borowczyk M, Jodlowska-Siewert E, Filipowicz D, Komarnicki P, Verburg F, Ziemnicka K, et al.
Pol Arch Intern Med
. 2025 Jan;
135(2).
PMID: 39764798
Introduction: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, with incidence rising in recent decades. Despite a favorable prognosis, management remains complex, often involving thyroidectomy followed by radioactive...
2.
Prevalence of Second Primary Malignancies in Patients With Well-Differentiated Neuroendocrine Tumors
Wolinski K, Komarnicki P, Maciejewski A, Musialkiewicz J, Gut P, Ruchala M
Endocr Pract
. 2025 Jan;
PMID: 39756679
Objective: Neuroendocrine tumors (NETs) constitute a diverse group of tumors. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25%...
3.
Kaluzna M, Katulska K, Ziemnicka K, Kompf P, Budny B, Komarnicki P, et al.
Endocr Connect
. 2024 Dec;
14(2).
PMID: 39719010
Introduction And Objectives: Isolated hypogonadotropic hypogonadism (IHH) may be associated with pituitary gland and olfactory system disorders. We aimed to correlate findings of magnetic resonance imaging (MRI) of the pituitary...
4.
Musialkiewicz J, Komarnicki P, Ziolkowska P, Czepczynski R, Ruchala M, Gut P
Pol Arch Intern Med
. 2024 Jul;
134(9).
PMID: 39007670
No abstract available.
5.
Komarnicki P, Gut P, Cieslewicz M, Musialkiewicz J, Maciejewski A, Czupinska M, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893179
Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic, due to their diversity and the lack of suitable biomarkers. Multianalyte assays and the shift to an omics-based approach improve...
6.
Komarnicki P, Musialkiewicz J, Maciejewski A, Gut P, Ruchala M
Pol Arch Intern Med
. 2024 May;
134(7-8).
PMID: 38747359
No abstract available.
7.
Komarnicki P, Gut P, Musialkiewicz J, Cieslewicz M, Maciejewski A, Patel P, et al.
Endocr Connect
. 2023 Aug;
12(10).
PMID: 37552533
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms that occur in various locations throughout the body. Despite their usually benign character, they might manifest with distant metastases. N-terminal prohormone of brain...
8.
Demircan K, Chillon T, Bracken T, Bulgarelli I, Campi I, Du Laing G, et al.
Front Immunol
. 2022 Dec;
13:1022673.
PMID: 36518764
Introduction: Certain trace elements are essential for life and affect immune system function, and their intake varies by region and population. Alterations in serum Se, Zn and Cu have been...
9.
Komarnicki P, Musialkiewicz J, Stanska A, Maciejewski A, Gut P, Mastorakos G, et al.
J Clin Med
. 2022 Oct;
11(19).
PMID: 36233409
Neuroendocrine tumors are a heterogeneous group of neoplasms originating from the diffuse endocrine system. Depending on primary location and hormonal status, they range in terms of clinical presentation, prognosis and...
10.
Maciejewski A, Gut P, Stajgis P, Wolinski K, Komarnicki P, Ruchala M
Pol Arch Intern Med
. 2022 Aug;
132(11).
PMID: 35930234
No abstract available.